Idarucizumab

Idarucizumab
Monoclonal antibody
Type	Fab fragment
Source	Humanized (from mouse)
Target	Dabigatran
Clinical data
Trade names	Praxbind
Other names	BI-655075
AHFS/Drugs.com	Monograph
License data	US DailyMed: Idarucizumab;
Pregnancy; category	AU: B2;
Routes of; administration	Intravenous
ATC code	V03AB37 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Identifiers
CAS Number	1362509-93-0;
IUPHAR/BPS	8298;
DrugBank	DB09264;
ChemSpider	none;
UNII	97RWB5S1U6;
KEGG	D10741 ;
Chemical and physical data
Formula	C2131H3299N555O671S11
Molar mass	47782.71 g·mol−1

Idarucizumab, sold under the brand name Praxbind, is a monoclonal antibody used as a reversal agent for dabigatran.

Idarucizumab was developed by Boehringer Ingelheim. One study sponsored by the manufacturer found that idarucizumab effectively reversed anticoagulation caused by dabigatran within minutes.

It was approved for medical use in the United States and in the European Union in 2015.